Morphosis Capital has completed the sale of its stake in DocProcess, a Romanian business process automation company, to French data management and e-invoicing provider AGENA3000.

The deal marks a full exit for both Morphosis Capital Fund I and DocProcess’s founders, Daniela and Liviu Apolozan.

Founded in 2005, DocProcess has built a SaaS platform that digitises and streamlines critical business functions including procure-to-pay, order-to-cash, e-invoicing, and transport. 

The company today serves over 3,500 clients across industries such as finance, retail, logistics, healthcare, and energy. Its portfolio includes multinationals such as Carrefour, Unilever, Mondelez, and Lactalis, alongside leading Romanian businesses like Altex and Flanco. In 2024, the company generated revenues of more than €4.2m and EBITDA of €1.1m.

Sébastien Trichet, President of AGENA3000, said: “DocProcess is a company with remarkable potential that complements perfectly the digital solutions portfolio of AGENA3000. Its platform is among the most advanced on the market, and the team behind it has demonstrated not only strong technological expertise but also a deep understanding of today’s business landscape. Going forward, integrating DocProcess will allow us to accelerate our international expansion while relying on its proven infrastructure and capabilities.”

DocProcess founders Daniela and Liviu Apolozan added: “For us, DocProcess has always been more than just a business – it was a mission to redefine how companies collaborate and automate critical processes. We are proud of what we have accomplished over the past 20 years together with our exceptional team and grateful to our clients and partners for their trust. This transaction marks the beginning of a new stage for DocProcess with AGENA3000, an organization that shares our vision for the future of digitalization.”

Morphosis Capital’s exit is the second full divestment from Fund I, after selling Dr. Leahu Dental Clinics to Regina Maria in 2023. Meet Morphosis Capital and learn more about their exit strategies by joining CEE’s Largest Private Equity Conference in Warsaw. 

Partner Simona Gemeneanu noted: “Over the past years, with the support of the Morphosis team, the company had the resources and structure needed to evolve into a profitable SaaS business with international reach. Now, as part of AGENA3000, DocProcess is well-positioned to grow further in France and broaden its reach into the enterprise segment.”

The transaction was facilitated by Cristian Mîndru and Mihaela Posircă from Act Legal, who advised Morphosis Capital and DocProcess. AGENA3000 was advised by Wolf Theiss and Cornet Vincent Ségurel, with GTA Tax acting as tax advisor.

The deal underscores Morphosis Capital’s strategy of backing ambitious Romanian entrepreneurs and scaling their companies internationally, while positioning AGENA3000 to strengthen its footprint in France and across Europe.

If you think we missed any important news, please do not hesitate to contact us at news@pe-insights.com.

Can`t stop reading? Read more.